Royalty Pharma (NASDAQ:RPRX) reported quarterly sales of $568.00 million which missed the analyst consensus estimate of $663.22 million by 14.36 percent. This is a 16.96 percent decrease over sales of $684.00 million the same period last year.
Royalty Pharma Q1 Sales $568.00M Miss $663.22M Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.